Seviteronel
http://dbpedia.org/resource/Seviteronel an entity of type: Thing
Seviteronel (developmental codes VT-464 and, formerly, INO-464) is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer. It is a nonsteroidal CYP17A1 inhibitor and works by inhibiting the production of androgens and estrogens in the body. As of July 2017, seviteronel is in phase II clinical trials for both prostate cancer and breast cancer. In January 2016, it was designated fast-track status by the United States Food and Drug Administration for prostate cancer. In April 2017, seviteronel received fast-track designation for breast cancer as well.
rdf:langString
rdf:langString
Seviteronel
xsd:integer
47288627
xsd:integer
1098918581
rdf:langString
None
xsd:integer
18
xsd:integer
1610537
xsd:integer
32738723
xsd:integer
4
xsd:integer
17
xsd:integer
-1
xsd:integer
3
xsd:integer
3
xsd:integer
78357816
rdf:langString
CCCO
xsd:integer
1
rdf:langString
ZBRAJOQFSNYJMF-SFHVURJKSA-N
rdf:langString
VT-464; INO-464
xsd:integer
8
xsd:integer
250
rdf:langString
Seviteronel (developmental codes VT-464 and, formerly, INO-464) is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer. It is a nonsteroidal CYP17A1 inhibitor and works by inhibiting the production of androgens and estrogens in the body. As of July 2017, seviteronel is in phase II clinical trials for both prostate cancer and breast cancer. In January 2016, it was designated fast-track status by the United States Food and Drug Administration for prostate cancer. In April 2017, seviteronel received fast-track designation for breast cancer as well.
xsd:nonNegativeInteger
9452
xsd:string
1610537-15-9
xsd:string
8S5OIN36X4
xsd:string
78357816